Inactive

Request for Information (RFI) 1. RFI Number: RFI-W81XWH-22-P-7499 2. Agency: United States Army Medical Research and Development Command (USAMRDC) 3. Office: Congressionally Directed Medical Research ... Request for Information (RFI) 1. RFI Number: RFI-W81XWH-22-P-7499 2. Agency: United States Army Medical Research and Development Command (USAMRDC) 3. Office: Congressionally Directed Medical Research Program (CDMRP) 4. Contracting Office: United States Army Medical Research Acquisition Activity (USAMRAA), Fort Detrick, Frederick, MD. 5. Location: TBD 6. Synopsis: The Joint Warfighter Medical Research Program (JWMRP) provides an opportunity to advance previously funded Department of Defense (DoD) or Service medical research and development (R&D) projects that address the medical requirements of the Services. The JWMRP complements and enhances the Defense Health Program by facilitating the further development of promising industry and academic efforts. Each year a broad spectrum of R&D initiatives are considered under the JWMRP. The efforts are aligned to one of the six Joint Program Committee (JPC) scientific domains. These are: Medical Simulation and Information Sciences (JPC-1), Military Infectious Diseases (JPC-2), Military Operational Medicine (JPC-5), Combat Casualty Care (JPC-6), Radiation Health Effects (JPC-7), and Clinical and Rehabilitative Medicine (JPC-8). Through research efforts focused in advanced technology development and product demonstration and validation, the JWMRP offers a pathway to transition maturing medical solutions to the Military Health System (MHS) for the benefit of our Service members and other MHS beneficiaries. 7. Background: Congress appropriated $40M for this program in the “Consolidated Appropriations Act, 2020”, Public Law 116-93. Page 237 of Senate Report 116-103 states that the funds “shall be used to augment and accelerate high priority Department of Defense (DoD) and Service medical requirements and to continue both core and congressionally-directed prior year initiatives that are close to achieving their objectives and yielding a benefit to military medicine. These funds shall not be used for new projects or basic research, and they shall be awarded at the discretion of the Secretary of Defense following a review of medical research and development gaps, as well as unfinanced medical requirements of the Services.” 8. Objective and Purpose: The Government is seeking vendors with the capability to achieve the objectives for the requirement described below. All respondents must have previously received DoD funding for a project preceding the project discussed in the respondent’s response to this RFI, per the JWMRP Congressional language. Project Description: The purpose of this work specifically addresses W81XWH-20-RFIJWMRP JPC6/Casualty Care Research Program—reduction of acute secondary organ damage (burn conversion). The original fibronectin (FN)-derived peptide P12 limits burn conversion and speeds burn wound closure after intravenous (IV) infusion; however, P12 was found to be sensitive to neutrophil elastase and thereby minimally active topically. Therefore, an elastase-resistant peptide cNP8 has been engineered that also speeds wound closure, and reduces scarring when given IV. It is posited that topical cNP8, given its homology and similar cationic isoelectric point to P12, can be delivered, like P12, from TyroMats in early debrided, deep-dermal burns AND it will speed wound closure and reduce scarring as effectively as IV cNP8 therapy for deep-dermal burns. If true, this stable, portable, user-friendly, topical cNP8 therapy will be ideal for localized, severe burns during prolonged field care (PFC). Specific aims include: 1) Design, manufacture, and test TyroMat-based wound dressings that release cNP8 from eight hours (fast) to four days (slow); 2) Determine whether topical cNP8, delivered from TyroMat (fast) and TyroMat (slow), reduces burn injury progression, speeds wound closure, and mitigates scarring in a porcine burn model; and 3) Pre-Initial New Drug (IND) meeting for topical cNP8 in TyroMat(fast) and TyroMat (slow) to treat deep-dermal burns. 9. Information Requested in Capability Statement: Brief summary of relevant experience pertaining to the requirements described above (for example government, academia, or industry experience). Include the award number of the previous DoD award, which qualifies the respondent for this program. 10. North American Industry Classification System (NAICS) Code: The NAICS code for this potential action is 541715 (Research and Development in the Physical Engineering and Life Sciences, except Nanotechnology and Biotechnology) with a Size Standard of 1,000 employees. 11. Response Due Date: Interested parties should submit their RFI response electronically by 12:00 pm Eastern 03 November 2021 via e-mail to Matthew Teel at matthew.d.teel.civ@mail.mil. 12. Instructions to Responders: 12.1 The Government appreciates responses from all capable and qualified sources. 12.2 The Government welcomes input and will accept questions pertaining to this RFI; however, the Government reserves the right to answer or not answer all questions pertaining to this RFI. Only one set of questions per vendor will be accepted. Telephone requests will not be entertained. 12.3 The subject header of the e-mail for submission of questions and/or the RFI response shall be: [Company Name]-RFI-W81XWH-22-P-7499. 12.4 Interested firms should submit a response (Capability Statement) that demonstrates the Offeror’s capabilities identified in this RFI. The Capability Statement shall not exceed two (2) typed pages. 13. Disclaimer and Important Notes: In accordance with Federal Acquisition Regulation (FAR) 15.201, "Exchange with industry before receipt of proposals," and FAR 52.215-3, "Request for information (RFI) or Solicitation for Planning Purposes (SFP)," this RFI is for information and planning purposes only, at this time, and shall not be construed as a solicitation or obligation on the part of the USAMRDC. The purpose of this RFI notice is to gain market knowledge. This RFI is not expected to be a Request for Proposal or Invitation for Bid, nor does it restrict the Government to an ultimate acquisition approach. The Government is not obliged to award a contract or otherwise pay for the information provided in the responses received. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its responses are complete and sufficiently detailed to allow the Government to determine the organization's solution. Responders are advised that the Government is under no obligation to acknowledge receipt of the information received, or to provide feedback to respondents regarding any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in the System for Award Management at https://www.beta.SAM.gov. At this time, no solicitation exists; therefore, please do not request a copy of the solicitation. NO PHONE CALLS PLEASE. It is the responsibility of any potential vendor to monitor beta.SAM.gov for the release of any solicitation or synopsis. Responses to this notice will not be considered adequate responses to a solicitation. 14. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in submitted responses. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). Original Point of Contact POC: Matthew Teel, matthew.d.teel.civ@mail.mil